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 Abstract 
  Introduction:   The incidence of contrast-induced nephropathy (CIN) increases in high cardiovas-
cular risk patients. Chronic kidney disease (CKD) is a known risk factor for CIN development. In a 
previous report, we demonstrated that the mean reference renal artery diameter (RVD) is an im-
portant determinant of CKD in patients undergoing coronary angiography for ischemic heart 
disease. However, RVD was never tested as a predictor of CIN.   Aim:   To look at the predictors of 
CIN.   Methods:   A total of 218 consecutive patients undergoing coronary and renal angiography 
were enrolled from the cohort of the RAS-CAD study (NCT 01173666). CIN was defined as a rela-
tive increase in baseline serum creatinine   6  25% within 1 week of contrast administration.   Re-
sults:   The incidence of CIN was 22%. In a fully adjusted model, contrast medium dose (20 ml in-
crease, OR 1.12, 95% CI 1.06–1.19, p  !  0.001), iso-osmolar contrast media (OR 0.28, 95% CI 0.09–0.99, 
p   !   0.05), atherosclerotic renovascular disease (OR 2.69, 95% CI 1.32–5.48, p   !   0.05), and RVD 
(1 mm/1.73 m  2   increase, OR 0.59, 95% CI 0.41–0.86, p   !   0.05) had the greatest effect on outcome 
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and were identified as independent predictors of CIN. CKD was selected as a predictor of CIN only 
in a model without RVD.   Conclusions:   In patients undergoing coronary angiography for isch-
emic heart disease, RVD is a stronger predictor of CIN than CKD.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Contrast-induced nephropathy (CIN) is a common and serious complication of contrast 
media (CM) used in imaging studies and is the third leading cause of acute kidney injury in 
hospitalized patients   [1]  . The incidence of CIN is low in patients without cardiovascular risk 
factors   [2]   and increases in patients with high cardiovascular risk   [3]  . Patients who develop 
CIN after percutaneous coronary intervention are at an increased risk of both short- and 
long-term mortality   [3, 4]  . Therefore, it is important to identify high-risk patients to reduce 
the incidence of CIN.
    Many individual risk factors for the development of CIN have been detected. Chronic 
kidney disease (CKD) is one of the most important risk factors for CIN. However, the mean 
reference renal artery diameter (RVD) was never tested prospectively to predict CIN. In pa-
tients undergoing coronary angiography for ischemic heart disease, we detected that RVD 
and minimal luminal diameter (MLD) are stronger determinants of CKD than the severity 
of renal artery stenosis  [5] . We hypothesized that RVD could be a predictor of CIN, indepen-
dently of major confounders. We took advantage of a very well phenotyped high cardiovas-
cular risk population (the RAS-CAD study  [6, 7] ; NCT 01173666) to investigate these points. 
    Our aim was to look at the predictors of CIN in patients undergoing coronary angiog-
raphy for suspected coronary heart disease.
  M e t h o d s  
 Study  Population 
  The study conformed to the ethical guidelines of our institution, and informed consent 
was obtained from each participant. The primary outcome was the development of CIN, de-
fined as a relative increase in baseline serum creatinine (sCr)  1 25% within 1 week of contrast 
injection.
    Patients were considered to be eligible for the study if they (1) were older than 18 years 
of age, (2) were referred for coronary angiography for ischemic heart disease, and (3) pre-
sented a stable baseline sCr concentration. Criteria for exclusion were (1) intravascular ad-
ministration of an iodinated contrast medium (CM) within the previous month, (2) acute 
myocardial infarction, (3) pre-existing end-stage renal disease requiring dialysis, and (4) 
shock.
    The patients’ age, gender, and sCr value were used to determine the estimated glomeru-
lar filtration rate (GFR) according to the formula developed and validated using data  obtained 
from patients of the Modification of Diet in Renal Disease study   [8]  : GFR (ml/min/1.73 m  2 )  = 
186   !   (sCr) 1.154    !   age 0.203    !   0.742 (if female)   !   1.21 (if Black). We considered a GFR   ! 60 
ml/min/1.73 m  2   as CKD.
  CIN  Prevention  Protocol 
  All patients were hydrated before angiography according to the ejection fraction (EF). 
Patients with EF   1  30% received 1 ml/kg/h of saline intravenously starting 24 h before and 
ending 24 h after the coronary angiography. Patients with EF  ^  30% received 0.5 ml/kg/h of 40
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saline intravenously 24 h before until 24 h after the coronary angiography. All patients with 
sCr  1 1.2 mg/dl received N-acetylcysteine (1,200 mg) twice daily starting 24 h before and end-
ing 24 h after the coronary angiography.
    sCr was measured within 24 h prior to angiography and during the first week after the 
administration of CM. The total volume of injected CM was recorded. The iso-osmolar CM 
(IOCM) iodixanol and the low-osmolar CM (LOCM) iobitridol, iopromide, iohexol, and 
iomeprol were used in this analysis. In this report, we look at the group effect of LOCM on 
CIN development.
  Renal  Angiography 
  To define the patency of the renal arteries, selective renal arteriography was performed 
at the end of the cardiac catheterization in the anterior-posterior and oblique projection with 
a hand injection of 4–8 ml of CM. After calibration with the outer diameter of the contrast-
filled catheter was performed to provide a standard, the size of the renal arteries was mea-
sured. In stenotic vessels, RVD was measured before the stenosis or, when unavailable, after 
the post-stenotic dilatation. Two qualified observers blinded to the patients’ clinical informa-
tion reviewed the angiographies. Each renal artery patency was measured twice. The average 
of the two operations was recorded. The mean of the left and right RVD was used in this 
analysis. Atherosclerotic renovascular disease (ARVD) was defined as the presence of angio-
graphically evident renal artery stenosis.
  Statistical  Analyses 
 Statistical analyses were performed with SPSS 16 software (SPSS Inc., Chicago, Ill., USA). 
Continuous variables were reported using means and standard deviations. Categorical vari-
ables were described as counts and percentages. The clinical characteristics of patients with 
and without CIN were compared using analyses of variance for continuous variables and the 
    2   test for categorical variables. Multivariate logistic regression analysis was performed to 
identify independent predictors of CIN and to estimate odds ratios (OR). Risk factors that 
were significant in the univariate analysis (p   ^   0.20) were available for selection in the final 
model; a backward stepwise method was used to select the best subset of independent predic-
tors of CIN to avoid overfitting of the data. Three separate regression models were developed 
(model 1, 2 and 3, respectively). The set of variables tested in model 1 included all the uni-
variate predictors of CIN; the set of variables tested in model 2 included all the univariate 
predictors of CIN tested in model 1 with the exception of RVD, and in model 3, we forced 
the CKD into the model.
  R e s u l t s  
 Patients 
 During the 6-month enrollment period, we consecutively enrolled 218 patients undergo-
ing coronary angiography. Overall, the mean age of the patients was 64.2   8   10.6 years, 74% 
were males, and baseline sCr was 1.07   8   0.31 mg/dl. CKD was present in 57 patients (26%); 
the incidence of CIN was 22%. A total of 15 variables were associated (p   ^   0.20) with the 
development of CIN and were selected to be studied in multivariate analysis. The selected 
correlates included demographics (age and female gender), clinical characteristics (pulse 
pressure, CKD, ARVD, RVD, hypertension, and smoking), drug therapy (   -blockers,  ACE 
inhibitors/sartans, and nitrates), and several angiographic and/or procedural characteristics 
(coronary artery disease, IOCM administration, and CM dose). Baseline characteristics and 
univariate analysis for CIN are reported in   table 1  .41
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  M u l t i v a r i a t e   A n a l y s e s  
  Taking advantage of a logistic regression analysis for CIN development, the influence of 
various correlates on the outcome was evaluated. CM dose, IOCM, ARVD, and RVD had the 
greatest effect on outcome and were identified as independent predictors of CIN (model 1; 
 table 2 ). When we developed a model excluding RVD from the set of variables studied by mul-
tivariate analysis, CKD was selected as an independent predictor of CIN (model 2;   table 2  ). 
Therefore, we forced the variable CKD into the multivariate model (model 3;   table 2  ). In the 
latter model, CKD did not reach a significant level (OR 1.49, 95% CI 0.67–3.31, p = 0.33). The 
area under the ROC curve for model 1, 2 and 3 was 0.74 (95% CI 0.66–0.81, p   !   0.001), 0.71 
(95% CI 0.62–0.79, p   !   0.001), and 0.74 (95% CI 0.66–0.81, p   !   0.001), respectively.
Table 1.   Demographic and clinical data
Whole group
(n = 218)
CIN
(n = 48)
Non-CIN
(n = 170)
p value1
Age, years 64811 68811 63810 <0.05
Male sex 74 65 76 0.15
Weight, kg 75.8813.5 75.2814.9 75.9813.1 0.76
Height, m 1.6580.08 1.6480.07 1.6580.08 0.52
Body mass index 27.884.2 27.884.7 27.884.0 0.99
Body surface area, m2 1.8880.19 1.8780.20 1.8880.19 0.65
Systolic blood pressure, mm Hg 1318195 133823 131817 0.62
Diastolic blood pressure, mm Hg 78811 77811 79812 0.38
Pulse pressure, mm Hg 53815 56816 52815 0.20
Baseline sCr, mg/dl 1.0780.31 1.1280.41 1.0680.27 0.38
GFR, ml/min/1.73 m2 75823 74831 75820 0.81
CKD 26 38 23 <0.05
Dyslipidemia 77 75 78 0.70
Smoking 66 52 69 <0.05
Diabetes 38 44 37 0.36
Hypertension 84 92 81 0.08
Stroke 10 11 9 0.80
Peripheral vascular disease 24 27 23 0.55
Therapy
Statins 53 60 52 0.35
Diuretics 28 31 27 0.64
-Blockers 40 52 36 0.06
ACE inhibitors/sartans 54 64 52 0.14
Calcium antagonists 19 17 19 0.69
-Blockers 6 5 6 0.75
Nitrates 34 48 30 <0.05
Coronary artery disease involved <0.05
None 9 4 11
1 vessel 33 23 36
2 vessels 23 23 24
3 vessels 34 50 30
ARVD 35 50 31 <0.05
RVD, mm/1.73 m2 5.4880.97 5.2480.98 5.5780.97 <0.05
CM dose, ml 2028132 2658175 1858112 <0.05
IOCM 17 10 18 0.20
Hydration, 0.5 ml/kg/h 8 13 7 0.16
N-acetylcysteine 30 40 28 0.11
V  alues are means 8 SD or percentages. 1 CIN vs. non-CIN.42
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  Discussion 
  For the first time, RVD, a factor associated with CKD   [5]  , has been examined as a risk 
factor for CIN. RVD was a stronger predictor of CIN than CKD in patients at high cardio-
vascular risk undergoing coronary angiography for ischemic heart disease.
    For the first time, our data provide evidence that RVD is a better predictor of CIN than 
CKD. In our study, prevalence of CKD was significantly higher in patients who developed 
CIN than in those who did not. Interestingly, when tested together with RVD, CKD was not 
selected as a predictor of CIN. CM dose, IOCM, ARVD, and RVD were the most important 
factors associated with CIN (model 1;   table 2  ). Due to its known impact on the development 
of CIN, we tested CKD as a possible predictor of CIN. When forced into the multivariate 
model (model 3;   table 2  ), CKD does not reach a significant level (p = 0.32). Therefore, we de-
veloped a model to test CKD as a determinant of CIN excluding RVD from the set of vari-
ables studied with multivariate analysis (model 2;  table 2 ). As expected, in model 2, CKD was 
selected as a predictor of CIN. Therefore, our analysis confirmed that CKD is a predictor of 
CIN but led to the conclusion that RVD is a better predictor of CIN than CKD in patients at 
high cardiovascular risk.
    CIN is classically attributed to vasoconstriction after iodinated CM injection   [2, 9]  . 
There is evidence that IOCM reduced the risk of CIN when compared to LOCM   [10]  . Our 
data confirm that the use of the IOCM iodixanol is associated with a reduced risk of CIN 
compared to LOCM. Moreover, our results confirm that the risk of CIN increases depending 
on CM dose, suggesting that coronary angiography in high-risk patients should be designed 
so that excessive volumes of CM are avoided; thus, the IOCM iodixanol should be preferred.
    RVD could be related to GFR by several mechanisms. In case of stenosis, MLD could 
represent the limiting factor for kidney blood flow, while in the absence of stenosis, RVD 
could be determined by blood flow through flow-mediated dilation. The reduction of RVD 
may be the consequence of a decreased renal blood flow. Arterial diameter is dependent on 
several dynamic factors, among them the level of vascular tone on the short term and vascu-
lar remodeling on the long term. It is well known that long-term changes in local hemody-
namic forces induce remodeling of arterial wall tissue, which is critical to vascular adapta-
Table 2.   Multivariate logistic regression analyses for CIN
OR 95% CI p value
Model 1
CM dose (20 ml) 1.12 1.06–1.19 <0.001
IOCM 0.28 0.09–0.99 <0.05
ARVD 2.69 1.32–5.48 <0.05
RVD (1 mm/1.73 m2) 0.59 0.41–0.86 <0.05
Model 2
CM dose (20 ml) 1.11 1.05–1.17 <0.001
IOCM 0.32 0.11–0.99 <0.05
ARVD 2.23 1.09–4.55 <0.05
CKD 1.95 0.91–4.16 0.09
Model 3
CM dose (20 ml) 1.12 1.06–1.19 <0.001
IOCM 0.28 0.09–0.91 <0.05
ARVD 2.47 1.19–5.14 <0.05
RVD (1 mm/1.73 m2) 0.62 0.43–0.91 <0.05
CKD 1.50 0.68–3.33 0.3243
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tion in the adult and to the progression of cardiovascular disease   [11]  . Sustained reductions 
in blood flow lead to flow-induced decreases in shear stress and inward arterial remodeling 
with a narrowing of lumen diameter  [12] . Clinically significant arterial occlusive disease de-
pressurizes the arterial tree downstream from the occlusion site and reduces the wall shear 
stress. Arterial remodeling limits change in wall shear stress   [13]  .
    In a previous study   [5]  , we detected that in patients with low RVD or low MLD the OR 
for CKD was markedly elevated. The association between RVD and CKD was confirmed in 
a fully adjusted model. In the present study, we extended the predictive power of RVD pro-
spectively and reported that RVD is an independent predictor of renal function impairment 
after CM administration in high cardiovascular risk patients. 
    To our knowledge, this is the first time that RVD was tested in a model for CIN includ-
ing ARVD. We detected that CIN incidence is increased in patients with ARVD and that a 
reduction of mRAC predisposes to a higher incidence of CIN. The clinical implication of 
these data is the promising role of renal artery patency as a predictor of GFR reduction after 
CM administration. Further analyses are needed to examine the etiology of CIN.
  Our CIN prevention protocol, developed according to patients’ EF and baseline sCr, con-
sisted in hydration and N-acetylcysteine. Several studies identified volume depletion as a risk 
factor for the development of CIN; as a result, fluid administration is frequently recommend-
ed   [13, 14]  . However, patients with low EF are more prone to congestive cardiac failure than 
patients with normal EF. In these patients, an over-hydration may dramatically increase the 
risk for heart failure. Therefore, we reduced the hydration in patients with EF   ^ 30%.  N-
acetylcysteine, a free radical scavenger with reported vasodilatory effects, has been reported 
in trials and in a recent meta-analysis to prevent CIN   [15, 16]  . A 3-fold reduction in the inci-
dence of CIN was reported in CKD patients undergoing elective coronary angiography fol-
lowing the administration of oral N-acetylcysteine (600 mg) in addition to intravenous iso-
tonic saline   [15]  . Recent studies suggest that higher doses of N-acetylcysteine may provide a 
significant protection against CIN: treatment with 1,200 mg N-acetylcysteine given orally 
twice daily on the day before and the day of contrast exposure was associated with a lower 
risk of CIN compared with 600 mg N-acetylcysteine   [17]  . In addition, N-acetylcysteine side 
effects and drug interactions are very rare with continued use and are highly unlikely to re-
sult from the limited use for renal protection. Therefore, we used N-acetylcysteine (1,200 mg 
twice daily) in patients at higher risk of CIN.
    The major limitation of this study was that the renal angiography was performed with-
out 3D reconstruction of the renal artery. This may have led to an underestimation of the 
real prevalence and significance of ARVD. Another limitation of this study was that the 
LOCM iobitridol, iopromide, and iomeprol were analyzed together, assuming a comparable 
effect on outcome.
  Conclusions 
  In high cardiovascular risk patients undergoing coronary angiography for ischemic 
heart disease, RVD was a stronger independent predictor of CIN than CKD.
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